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Iranian J Parasitol: Vol.  5 , No. 3 , 20 10 , pp .   11 - 19     11                   Original Paper     Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Su p- plemen tary with  Meglumine Antimoniate ( Glucantime®) Against  Cutaneous Leishmaniasis In BALB/C Mice     F Zamani Sorkhroodi 1 , * AM Alavi Naeini 1 , AR Zahraei Ramazani 2 ,  MR  Aghaye Ghazvini 3 ,   M  Moh e bali 4 ,   SA Keshavarz 1     1 Dept. of Nutrition and Biochemistry, School of Health, Tehran University of Medical Science, Iran   2 Dept. of Entomology, School of Health, Tehran University of Medical Science, Iran   3 Isfahan Center of Public  Health Training and Research, Institute of Public Health Research, Tehran Un i- ver sity of Medical Science, Iran   4 Dept. of Medical Parasitology and Mycology, School of Health, Tehran University of Medical Science,  Iran     (Received  15   Jan  2010 ; accepted  11   Jun e  2010)   ’ Abstract   Background:  Successful therapy of leishmaniasis depends on effective cellular immune response. We  evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in  combination with Glucantime® in trea tment of cutaneous leishmaniasis lesions r e sulting from  Leishmania  ma jor  in susceptible animal model.   Methods:  Thirty three female mice weighing 18 - 20 g at the age of 7 - 8 week infected with  L. m a jor  were  randomly divided into 3 groups:  group1 :   treated by  sodium selenite (0.35 mg/kg for 30 days), group2:  treated by zinc sulphate (2 mg/kg for 30 days) and group3: treated by distilled w a ter (0.01 ml/gr body  weight for 30 days) as control. All groups received Glucantime® as a sta n dard anti -  leishmanial agent  (60  mg/kg, ip) for 14 days. To assess the results of treatment mea s urement of lesions size and parasitological  tests were done weekly.   Results:  The lesion sizes increased continuously  in sodium selenite group .Although ,  in zinc group did not  in crease comp ared to baseline   But with considering the time -  group interaction there was no significant  difference between zinc and control group  during this study.  There was no difference between lesion sizes  and Leishmanial loads in the interventional and control gr oups, respectively.    Conclusion:  Sodium selenite and zinc sulphate at mentioned doses and duration of treatment did not show  any treatment effect on cutaneous leishmaniasis  caused by  L. major  in BALB/c  mice. Increasing the dose  of supplements and consideri ng the follow up period after treatment can help more certain conclusion.   Key words:   Leishmania major , Sodium selenite, Zinc sulphate,  Meglumine Antimoniate  (gl u cantime®),  BALB/c                  Iranian Society of Parasito l ogy   http:// isp.tums.ac.ir     Iranian J Parasitol     Open access Journal at   http:// ijpa.tums.ac.ir       Tehran University of Med i cal  Sciences Public a tion   http:// tums.ac.ir       * Corresponding Author:   Fax: 0311 - 5512944, E - mail: amalavi@tums.ac.ir  Zamani  Sorkhrodi et al.:Therapeutic Effect of Sodium Selenite…   12   Introduction     utaneous leishmaniasis is an infection  caused  by  Leishman ia   protozoa,  which are usually transmitted by the  bite of various species of phl e botomine sand  flies (1).   It is endemic in 88 countries. A p- proximately 350 million people are thought  to be at risk. Cutaneous  l eishmaniasis due to  L.  major   (CLM)  is  a  great  he alth  problem  and prevails in rural di s tricts of 16 out of 30  provinces in Iran (2).    O ne of the most effective drugs in leishm a- ni asis  treatment, which  used  systemati cally,   is  pentavalent  antimonies  such  as  Gluca n- time® (3) .   In  human  and  experimental  cutan eous  leishma niasis,  development  of  protective  immunity is d e pendent on the generation of  INFγ - producing  T  cells.  INFγ  activates  i n - fected macrophages to eliminate the parasite  via  reactive  oxygen  and  reactive  nitr o - gen(4) .Both of these intermediates reac tive  oxygen intermediates (ROI) and reactive n i- tro gen intermediates (RNI) are important in  macrophages  and  in  vitro  suppression  of  each intermediate resulted in failure of pr o- to zoa killing in macrophages (5).   Recent studies in animal models showed that  s uccessful leishmaniasis therapy depends on  effe c tive  cellular  immune  response.  Thus  immunotherapy should be used in combina - tion with chem o therapy (6, 7). Therefore, we  can  use  immunomodulator  components  as  valuable tools to modulate and enhance i m - mune  re sponses.  Experimental  studies  showed  that  zinc  deficiency  could  change  immune  functions  from  cellular  Th1  r e - sponses to humoral Th2 response (8). On the  other hand, zinc deficiency could be resulted  some skin lesions (9, 10).    Although, the other  in vitro   and  in vivo  stu d - ies have shown antileishmanial effect of zinc  sulphate, this supplement in one of the h u - man study was less effective in comparison  with Glucantime® (11).    There are different reports about oxidative  stress and probable effectiveness of an tiox i - dants  in  leishmaniasis   (12 - 14).  Selenium  is  one of the important cellular antioxidants (9).  There is a fai l ure in Th1 cytokine production  in parallel with selenium deficiency and sup - plementation with selenium in selenium d e- fi cient animals results i n IL2 secretion which  is secreted from Th1 (15). In addition,  in v i- tro  studies have shown that sodium s e lenite  can  inhibit  Leishmania  donovani   growth  through blocking of polyamine biosyn thesis  (16).  Studies  have  shown  signifi cant  d e- crease in serum selen ium and its related e n- zyme glutathione pe r oxidase (17).   With considering few studies in sodium se - lenite and oral zinc effectiveness in cutan e - ous leishmaniasis treatment and positive e f - fects of antioxidants (selenium and zinc) on  host’s  i m mune  function  a nd  in  the  other  hand, negative effects via free radicals trap - ping which are impo r tant in macrophage, we  decided to evaluate the effectiveness of oral  sodium selenite and zinc sulphate as  imm u- no modulator  in  combin a tion  with  stan dard   chemotherapy  (Glucan time®  )against  cut a- neous  leishmaniasis  caused  by  L. major   in  BALB/c.       Materials and Methods     Animals   Thirty - three  female  BALB/c  mice  of  a p- proxi mately 18 - 20 g weight at the age of 7 - 8  week were used in this experimental study.  All  mice  were  housed  in  clim atically  co n- trolled  room  in  plastic  cages  and  fed  with  standard rodent food pellet.     Parasites   Leishmania  major   (MRHO/IR/75/ER)  Iran  reference  strain  was  obtained  from  the  C  Iranian J Parasitol: Vol.  5 , No. 3 , 20 10 , pp .   11 - 19     13   School of Pu b lic Health, Tehran University  of  Medical  Science,  Iran  in  NNN  medium  an d then a sub - cultured to RPMI1640 as e n - riched liquid medium.        Immunomodulator  supplement  and  a n - tileishmanial drug   The immunomodulator supplement was s o - dium selenite :( Merck, 0.35 mg/kg) and zinc  sulphate : (Razi company, 2 mg/kg) and dis - tilled water  as placebo. Ampoules of meglu - mine antimoniate (Glucantime®) pu r chased  from Spica, France were used 60 mg/kg (1).      Experimental protocol   After  disinfection  of  injection  site,  0.1 - 0.2  ml  of  culture  medium  containing  at  least  2×10 6  pr o mastigote at stationa ry phase in 0.1  ml, injected at the base of BALB/c tail su b- cu taneously.  The weight and diameter of l e- sions  were  measured  before  treatment.  Im - pression smears were pr e pared from lesions;  methanol  fixed,  and  stained  with  10%  Geimsa stain in water.   Almost o ne month  after  injection  and  appearance  of  lesions,  treatment started. Thirty and three BALB/c  mice were randomly divided into 3 groups as  follows:  group1 :   treated by sodium selenite  (0.35 mg/kg for 30 days), group2: treated by  zinc  sulphate  (2  mg/kg  for  30  days)  and  group3: treated by di s tilled water (0.01 ml/gr  body  weight  for  30  days)  as  control.  All  groups received Glucantime® as a standard  anti -  leishmanial agent (60 mg/kg, ip) for 14  days.   To  assess  the  results  of  treatment,  size  of  lesions  measured  weekly  up  to  the  end  of  treatment.  Microscopy slides were also pr e - pared,  fixed  with  methanol,  stained  by  Geimsa and  examined by  light microscopy  (× 1000).  The parasite density is graded a c - cording to grading of  Leishmania  parasites  (19).  Treatment eff i cac y was determined by  comparing the diameters of skin lesions and  the  presence  of  amastigote  forms  between  intervention and control groups.       Statistical Analysis   The results are given as mean ± SEM values.  The significance   of the mean difference b e - tween gr oups was assessed by the Student’s   t - test  and  repeated  ANOVA.  Parsitologic  results were co m pared by chi -  square test.         Results   The mean of lesion size in sodium selenite  group, zinc sulphate group and control group  was 3.4±0.2 mm, 3.4±0.5 mm and 3.4±0.4  mm  after  30  days  post  treatment,  respec - tively. There were no significant diffe r ence  between treatment groups and control group  at  baseline.  The  mean  of  lesion  sizes  in - creased in s o dium selenite and control group  compared to baseline and there were no di f- fer ence between these two  groups (Table1,  Fig.  1).  The  mean  of  lesion  size  in  zinc  group did not increase compared to baseline.  However, with considering the time -  group  interaction  there  was  no  significant  diffe r - ence between zinc and control group (Tabl e1,  Fig. 2).     After 4 weeks of treatment, there was no st a- tis tical difference in parasitological tests of  lesions between  treatment  groups  and  co n - trol group (Table2).              Zamani  Sorkhrodi et al.:Therapeutic Effect of Sodium Selenite…   14   0 0.1 0.2 0.3 0.4 1 2 3 4 5 time(week) lesion size (mm) sodium selenite control     Fig. 1:  Mean of lesion sizes (mm) during treatment period in sodium selenite  group compared  with control group         0 0.5 1 1.5 2 2.5 3 3.5 4 1 2 3 4 5 time(week) lesion size(mm) zinc sulphate control     Fig. 2:  Mean of lesion sizes (mm) during treatment period in zinc sulphate group compared with  control group    Iranian J Parasitol: Vol.  5 , No. 3 , 20 10 , pp .   11 - 19     15   Table 1 : Therapeutic effect of  zinc sulphate and sodium selenite on  the lesion sizes (mm) of  local ized c utaneous leishmaniasis caused by  L. major  in BALB/c mice compared to control  groups       Group   No   Lesion Size(mm)   Before Intervention X *  ±2SD **   Lesion Size(mm)   After Intervention X *  ±2SD **        direction   P  value   Zinc Sulphate   11      2.8 ±0.3      3.4 ±0.5   ↑     0.57     Sodium Selenite   11   2.4± 0.3   3.4± 0.2   ↑   0.73     Control     11   1.8± 0.4   3.4 ±0.4   ↑   -     * =mean   **=standard deviation   The mean lesion sizes, were not decreased significantly before ( P = 0.57) and 4 weeks ( P =0.73)  a f ter treatment by   a two - way analysis of varianc e ( ANOVA).                                 Table 2:  Parsitologic tests of lesions of localized cutaneous leishmaniasis caused by  L. major   in BALB/c mice compared to control groups     1  Grading of  Leishmania  parasites   2  Not significant   1+: 1 - 10 parasite/1000 fields   2+:1 - 10 parasites/100 fields   3+: 1 - 10 parasites/10 fields   4+  &  more: more than  10 parasites/10 fields         Group 1   without  l e sion   0   1+   2+   3+   4+ &  more      P   value   Sodium Selenite(n=11)   0   1   1   3   2   4   Zinc    Sulphate   (n=11)     0   1   1   3   2   4   Control (n=11)     2   1   1   5   1   1       NS 2              P =0.16  Zamani  Sorkhrodi et al.:Therapeutic Effect of Sodium Selenite…   16   Discussion     Leishmaniasis is a worldwide parasitic dis - ease currently treated with expensive com - pounds and severe side effects, and are fre - quently ineffective, emphasizing the impo r - tance to search new compounds against this  d isease. The standard agents for leishman i - asis  such  as  pentavalent  antimonials,  pe n - tamidine, and amphotericin B and miltefo s - ine have the disadvantages of repeated pa r - enteral injection and of toxicity (18, 19).   All  groups  received  Glucantime®  but  the  mea n  of  lesion  size  increased  during  the  treat ment p e riod and there was no significant  difference  between  zinc  and  control  group  and also between s e lenite and control group.  Maybe high sensitivity of this animal model  against  L. major  (20)  is  the cause of th is pro - gressive  process,  although  sodium  s e lenite  has antileishmanial activity against  L. major   promastigotes  in  vitro   (16).  In  the  pr e sent  investigation,  sodium selenite  had no activ - ity  at  the  dose  of  0.35  mg/kg  in  vivo   and  there were no difference betwe en treatment  and  control  group  in  parasitological  tests.  This  dose  had  low  toxi c ity  in  mice  (21).  Maybe the use of higher doses had different  effect in cutaneous leishmaniasis treatment.  Moreover,  we  used  WHO  grading  of  Leishma nia  parasites for lesion. Ma ybe this  grading  cannot  show  the  exact  difference  between groups (22).     Reactive  oxygen  intermediates  (ROI)  and  reactive  nitrogen  intermediates  (RNI)  are  responsible  for  parasite  killing  in  macro - phages and suppression of each radicals i n- hib its macrophag e activity (5). In Bisti study,  iron  injection  as  oxidant  in  inhibited  the  parasite growth and progress in lesion size  (23) which indicates the role of free radi cals  in leishmaniasis treatment. Maybe the ant i- oxidant role of selenium (9) is the cause of  th is result.   Three  studies  showed  the  effectiveness  of  zinc sulphate injection in treatment of cut a- ne ous  leishmaniasis  (24 - 26).  Neverthe less,  oral zinc had different effects. Zinc sul phate  was  effective  in  treatment  of  cutane ous  leishmaniasis at the dose  of 10 mg/kg for 5  days in mice (27). These r e sults indi cate that  high  doses  in  short  time  is  more  effective  than low dose in long time.  This study used  MHOM/IQ/93/MRC6 strain that is different  from our parasite strain. Maybe our di f ferent  result is due  to this issue.   In another study (28), zinc sulphate was e f- fec tive in treatment of cutaneous leishman i - asis at the dose of 2 mg/kg for 45 days in  human. The treatment time and zinc dose is  similar to our study but the probable cause  of different result is  the sensitivity to  L. m a- jor  causes cutaneous leishm a niasis in hu man  but it can cause both visceral and cutane ous  leishmaniasis in Balb/c (20). The dose of 2  mg/kg can stimulate i m mune sys tem of mice  (29). Higher doses have genotoxic effect on  mice (30).  Oral zinc did not have any effect  on acute cutaneous leishmaniasis (11). In 60   p a tients  with  cutane ous  leishmaniasis  and  the control group of 100 healthy volunteers  from the same area, levels of serum Zn were  signifi cantly  lower  than  the  control  group  ( P <0.001) (31). In Faryadi et al. study there  was  also  similar  results (32),  in  which  the  acute  and  chronic  cutaneous  leishmaniasis  patients had significantly lower Zn level as  compared to the control subjects (32).   Two recent studies have suggested the us e of  blood zinc concentration as a means for e s ti - mating the prognosis of CL (31, 32). In our  study,  oral  zinc  sulphate  as  a  supplement  was mostly effective compared to the bas e - line in treatment of cutaneous leishmaniasis.    The cause of acute cutaneous le ishmaniasis  is  L. tropica , which is different from  L. ma - jor .  In v i tro  studies showed dose dependent Iranian J Parasitol: Vol.  5 , No. 3 , 20 10 , pp .   11 - 19     17   anti - Leishmania  effect of zinc sulphate (30).  Maybe  higher  dose  had  effectiveness  on  treat ment although it has genotoxic effect.  ¼  In conclusion, results  of the present invest i- ga tion  indicate  that  sodium  selenite  at  the  dose of 0.35 mg/kg and zinc sulphate at the  dose of 2 mg/kg does not have any effect on  cutaneous leishman i asis treatment in ani mal  model. Use of higher doses and consider ing  a follow up  period may help the certain co n- clusion.      Acknowledgements     The authors would like to thank all staff of  Dep. of Medical Parasitology and Mycology,  School of Public Health, Tehran University  of  Medical  Science  and  Isfahan  Research  Center, National Institut e of Health Research  (NIH) of Iran who have helped with this sur - vey.  The authors declare that they have no  conflicts of interest.      References     1 .   World  Health  Organization  (WHO),  1990. The leishmaniasis. Technical re port,  pp.793, 27.   2 .   World  Health  Organiza tion  (WHO),  2000. Leishmaniasis and  Leishma nia /HIV  co i n fection, WHO/CDC/CSR/ISR, pp.1 - 2.   3 .   Tuon FF, Amato VS, Graf ME, Siqueira  AM,  Nicodemo  AC,  Amato  Neto  V.  Treatment  of  New  World  c u ta neous  leishmaniasis -- a system atic review with a  meta - analysis. Int J  Dermatol. 2008 Feb;  47(2):109 - 24.     4 .   Von Stebut E. Immunology of cutane ous  leishmaniasis:  the  role  of  mast  cells,  phagocytes and dendritic cells for prote c- tive  immunity.  Eur  J  De r matol.  2007;  17(2):115 - 22.   5 .   Murray  HW,  Nathan  CF.  Macro phage  microbicidal mec hanisms in vivo: reactive  nitrogen  versus  oxygen  intermediates  in  the  killing  of  intracel lular  visceral  Leishmania dono vani. J Exp Med. 1999;  189(4):741 - 746.   6 .   Kharazmi A,  Ke mp K ,  Ismail A ,  Gasim S ,  Gaafar A , Kurtzhals JA,  El Hassan AM ,  Theander TG,  Kemp M .  T - cell response  in  human  leishmani asis.  Immunol  Lett.  1999; 65(1 - 2):105 - 8.   7 .   Li J, Sutterwala S, Farrell J.P. Suc cessful  therapy of chronic, nonheal ing murine c u- taneous  leishmaniasis  with  sodium  st i- bogluconate  and  gamma  interferon  d e- pends on contin ued i nterleukin - 12 produ c - tion.”Infection  and  immunity,  1997;  65(8):3225 - 3230.   8 .   Sprietsma  JE.  Zinc - controlled  Th1/Th2  switch  significantly  deter mines  develo p- ment of di s eases. Med Hypothesis. 1997;  49(1):1 - 14.   9 .   Mahan  LK,  Escott - Stump  S  (eds).  Krause’s  Food  and  Nu trition  therapy.  2008; 11th ed, WB Saunders Co, Phila - delphia; pp: 39 - 135.   10 .   Van Weyenbergh J, Santana G, D'Oliveira  A Jr, Santos AF Jr, Costa CH, Carvalho  EM,  Ba r ral  A,  Barral - Netto  M.  Zinc/copper  imbalance  re flects  immune  dysfunction in human leishman i asi s: an ex  vivo and in vitro study. BMC Infect Dis.  2004;17,4:50.   11 .   Yazdan  Panah  MJ,  Mostoufi  SK,  Soleimani  M.  Oral  Zinc  Sulfate  in  the  treatment of acute cutaneous  Leishman i- asis.  IR J Dermatol.   2003; 22(6): 24 - 20(In  Persian).   12 .   Serarslan G, Ylmaz HR, Sugut S.  Se rum  antioxidant  activities,  malondialde hyde  and nitric oxide lev els in human cutaneous  leishmani asis. Clin Exp Dermatol. 2005;  30(3):267 - 71.   13 .   Vural H, Aksoy N and Ozbilge H. Al - teration of oxid a tive - antioxidative status in Zamani  Sorkhrodi et al.:Therapeutic Effect of Sodium Selenite…   18   cutaneous  leishmaniasis.  Cel l  Biochem  Funct.2004; 22(3):153 - 156.   14 .   Bildik A, Kargin F, Seyrek K, Pasa S, O z- ensoy  S.  Ox i dative  stress  and  non - enzymatic  ant i oxidative  status  in  dogs  with visceral leishmaniasis. Res Vet Sci.  2004; 77(1):63 - 6.   15 .   Hoffmann PR, Berry MJ. The influ ence of  selen ium on immune r e sponses. Mol Nutr  Food Res. 2008: 52(11):1273 - 80.   16 .   Mukhopadhyay R, Madhubala R. Ef fect  of antioxidants on the growth and pol y- amine  levels  of  Leishmania  donovani.  Biochem Pharmacol. 1994; 74(4):611 - 5.   17 .   Kocyigit A, Erel O, Gurel M.S , Seyrek  A,  Aktepe N, Avcı Ş . Decreas ing selenium  levels and glu tathione peroxidase activity  in pa tients with cutaneous leishmaniasis.  Tr J of Medical Sciences. 1999; 29: 291 - 295.   18 .   Soto  J,  Arana  BA,  Toledo  J,  Rizzo  N,  Vega JC, Diaz A, Luz M, Gutierrez P,  Arboled a M, Berman JD, Junge K,Engel J,  Sindermann H. Miltefo s ine for new world  cutaneous leishmani asis. Clin Infect Dis.  2004, 1; 38(9):1266 - 1272.   19 .   Mohebali M,  Fotouhi A, Hooshmand B,  Zarei  Z,  Akhoundi  B,  Ra h nema  A,  Razaghian A.R, Kabir M.J    , Nadim A.  Comparis on  of  miltefosine  and  me - glumine  antimoniate  (Glucanti me R )  for  the  treatment  of  zoonotic  cuta neous  leishmaniasis  (ZCL)  by  a  randomized  clinical  trial  in  Iran.  Acta  Tropica.  2007;103(1):33 - 40.   20 .   Rossi - Bergmann B, Müller I, Godinho EB.  TH1 and TH2 T - cell sub sets are differe n- tially  a c tivated  by  macrophages  and  B  cells in murine leishmaniasis. Infect I m- mun. 1993; 61(5):2266 - 9.   21 .   Ozonlins  TR,  Sikasay  DL,  Wells  PG.  Modulation of embryonic glutathion pe r- oxidase  acti v ity  and  phenytoin  tera - togenicity by dietary depr ivation of sel e- nium in CD - 1 mice . J Pharma col Exp  Ther. 1996; 277 (2): 945 - 53.   22 .   World Health Organization . Basic labor a- tory  methods  in  medical  parasitology  1991; Sec tion1.pp:58 - 61.     23 .   Bisti S, Konidou G, Boelaert J et al. The  prevention of growth of  Leishm a nia   major   progeny  in  Balb/c  iron - loaded  mice:  a  process  coupled  to  increased  oxidative  burst, the ampli tude and duration of which  de pend   on initial parasite developmen tal  stage and dose.” Microbes and in fection.  2006; 8(6):1464 - 72.   24 .   Iraji F, Vali A, A siliyan A, Shah Talebi  MA.   Comparison  of  intralesion ally  i n- jected Zinc Sulfate and Pentavalent Ant i- mony com pound in treatment of acute c u- tane ous Leishmaniasis.  J Ke r man Univer - sity Med Sci   2000; 4(7): 166 - 161.   25 .   Sharquie  KE, Najim  RA,  Farjou  IB.  A  compara tive  controlled  trial  of  in - tralesionally - administerd zinc sulfate, h y- pertonic  chloride  and  pentavalent  an - timony compound against acute cuta neous  leishmaniasis.  Clin Exp Dermatol. 1997;  22(4):169 - 73.   26 .   Firooz AR, Khatami AR, Khamesi pour A,  Nassiri Kashan i M, Ni l foroushzadeh MA,  Behnia F, Pazoki Toroudi HR, Dowlati Y.  A compari son between the efficacy of i n- trale sional injection of 2% Zinc Sulfate so - lution with Glucantime® in the treatment  of acute old world cutane ous Leishman i- asis:  A  randomized,  dou b le - blind,  co n- trolled clinical trial. IR J Dermatol   2004;  28(7): 218 - 209.   27 .   Najim RA, Sharquie KE, Faarjou IB. Zinc  sulfate  in  the  treatment  of  cut a ne ous  leishmaniasis: an in vitro and animal study.  Mem Inst Oswaldo Cruz, Rio de Janeiro.  1998; 93(6):831 - 837.   28 .   Sharquie KE, Najim RA, Farjou IB, Al - Timmy DJ .Oral zinc sulfate in the trea t- ment  of  acute  cutaneous  leishmaniasis.  Clin Exp Dermatol. 2001; 26(1):21 - 6.   29 .   Obminiska - Domoradzka B, Szczypka M,  Debowy J. Effects thy momimetic drugs  and zinc supplemen tation on  the cellular Iranian J Parasitol: Vol.  5 , No. 3 , 20 10 , pp .   11 - 19     19   im mune r e sponse in hydrocortisone - sup - pressed mice.  J Vet Med B Infect Dis Vet  Public Health. 2002; 49(10):469 - 75.   30 .   Banu BS, Devi KD, Mahboob M, Jamil K.  In vivo genotoxic effect of zinc sulfate in  mouse peripheral blood leukocytes using  Com et assay. Drug Chem Toxicol. 2001;  24(1):63 - 73.   31 .   Pourfallah  F,  Javadian  S,  Zamani  Z,  Saghiri  R,  Sadeghi  S,  Zarea  B,  Faiaz  Sh,Mirkhani F, Fatemi N. Evaluation of  serum  levels  of  zinc,  copper,  iron,  and  zinc/copper ratio in cutaneous leishman i- asis.   Iranian J Arthropod - Borne Dis. 2009;  3(2): 7 - 11.   32 .   Faryadi M, Mohebali M. Alterations of s e- rum zinc, copper, and iron concen trations  in patients with acute and chronic cutan e- ous leishmaniasis. Iranian J Publ Health,  2003; 32(4):53 - 58.                                  